Journalartikel

Jahr der Veröffentlichung: 2015

Seiten: 90-94

Zeitschrift: International Journal of Cardiology

Bandnummer: 179

ISSN: 0167-5273

eISSN: 1874-1754

DOI Link: https://doi.org/10.1016/j.ijcard.2014.10.032

Verlag: Elsevier

Abstract: 

Objective: This study evaluates the feasibility of percutaneous coronary intervention with bioresorbable vascular scaffolds (BVSs) in chronic total occlusion (CTO) lesions. Background: Everolimus-eluting BVSs represent a new approach to treating coronary artery disease, but experience with CTO is limited.

Methods: Patients with a previously diagnosed CTO who had been treated with BVS were included. Patients with unsuccessful CTO procedures and patients treated with drug-eluting stents were excluded. Difficulty of the CTO procedure was assessed by the J-score.

Results: A total of 23 patients were included. Mean age was 60.4 +/- 9.0 years, 17.4% were female, 91.3% suffered from hypertension and 34.8% from diabetes. Mean J-score was 1.7 +/- 1.0. Median procedure time was 70 min (54-85), mean contrast volume was 213.5 mL (similar to 94.2) and median fluoroscopy time was 19.1 min (13.130.0). A total of 64 BVSs were implanted with a mean number of 2.8 +/- 1.0 BVSs per patient, a mean total BVS length of 64.8 +/- 24.2 mm per lesion, and a mean BVS diameter of 3.1 +/- 0.2 mm. Neither a scaffold-related dissection nor any other intra-procedural complication occurred. During a follow-up of 108 (79.5-214.5) days one in-scaffold thrombosis was noted 4 days after the CTO procedure due to a lack of dual antiplatelet therapy. No further major adverse cardiac events occurred.

Conclusion: These results suggest that BVS implantation in CTO lesions can be performed with good procedural success and reasonable clinical short-term outcome in highly selected cases. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

Harvard-Zitierstil: Wiebe, J., Liebetrau, C., Doerr, O., Most, A., Weipert, K., Rixe, J., et al. (2015) Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion, International Journal of Cardiology, 179, pp. 90-94. https://doi.org/10.1016/j.ijcard.2014.10.032

APA-Zitierstil: Wiebe, J., Liebetrau, C., Doerr, O., Most, A., Weipert, K., Rixe, J., Bauer, T., Moellmann, H., Elsaesser, A., Hamm, C., & Nef, H. (2015). Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion. International Journal of Cardiology. 179, 90-94. https://doi.org/10.1016/j.ijcard.2014.10.032